The FDA expanded the indication of HPV 9-valent vaccine, recombinant to include prevention of oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52 and 58, according to a manufacturer-issued press release.
HPV
A federal public health advisory panel said Wednesday that some people through age 45 could benefit from getting an HPV vaccine and should discuss the possibility with their doctors.